The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 0076

Estimated average burden

response:

hours per 4.00

1. Issuer's Identity	<u> </u>		
CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001733413			X Corporation
Name of Issuer			Limited Partnership
TFF Pharmaceuticals, I	nc.		H
Jurisdiction of			Limited Liability Company
Incorporation/Organiz	zation		General Partnership
DELAWARE			Business Trust
Year of Incorporation/Organization		Other (Specify)	
Over Five Years Ago			Other (Specify)
Within Last Five Yea	ars (Specify Year) 2018		
Yet to Be Formed			
2. Principal Place	of Business and Contac	t Information	
Name of Issuer			
TFF Pharmaceuticals, I	nc.		
Street Address 1		Street Address 2	!
2801 VIA FORTUNA, SU	JITE 425		
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
AUSTIN	TEXAS	78746	737-802-1979
3. Related Persons	5		
Last Name	First Name		Middle Name
Mills, Jr.	Robert		S.

Street Address 2

TEXAS

Relationship: X Executive Officer X Director | Promoter

State/Province/Country

ZIP/PostalCode

78746

Street Address 1

City

Austin

2801 Via Fortuna, Suite 425

Ciarincation of Response (if Neo	Lessary):	
Last Name	First Name	Middle Name
Windsor	Brian	
Street Address 1	Street Address 2	
2801 Via Fortuna, Suite 425	S	710 (0 10 1
City	State/Province/Country	ZIP/PostalCode
Austin	TEXAS	78746
Relationship: X Executive Office	cer X Director Promoter	
Clarification of Response (if Neo	cessary):	
Last Name	First Name	Middle Name
Coleman	Kirk	
Street Address 1	Street Address 2	
2801 Via Fortuna, Suite 425		
City	State/Province/Country	ZIP/PostalCode
Austin	TEXAS	78746
Relationship: X Executive Office	cer Director Promoter	
Clarification of Response (if Neo	cessary):	
Last Name	First Name	Middle Name
Fletcher	Aaron	
Street Address 1	Street Address 2	
2801 Via Fortuna, Suite 425		
City	State/Province/Country	ZIP/PostalCode
Austin	TEXAS	78746
Relationship: Executive Office	cer X Director Promoter	
Clarification of Response (if Neo	cessary):	
4. Industry Group		
Agriculture	Health Care	Retailing
Banking & Financial Services	Biotechnology	
Commercial Banking		Restaurants
H	Health Insuranc	Technology
Insurance	Hospitals & Phy	sicians Computers
Investing	Dharmacoutical	ς Π τ .μ
Investment Banking	X Pharmaceuticals	
Pooled Investment Fund	Other Health Ca	ore Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company		Airlines & Airports
the Investment Compan	y Commercial	
Act of 1940?		

Yes No	Construction	Lodging & Conventions
Other Banking & Financial	Services REITS & Finance	Tourism & Travel Services
Business Services	Residential	Other Travel
Energy		
Coal Mining	Other Real Estate	S Unter
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
5. Issuer Size		
Revenue Range OR	Aggregate Net Asset Va □	-
No Revenues	No Aggregate Net As	set Value
\$1 - \$1,000,000	\$1 - \$5,000,000	
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,0	000
\$5,000,001 -	\$25,000,001 - \$50,000	,000
\$25,000,000 \$25,000,001 -	H	
\$100,000,000	\$50,000,001 - \$100,00	0,000
Over \$100,000,000	Over \$100,000,000	
X Decline to Disclose	Decline to Disclose	
Not Applicable	Not Applicable	
6. Federal Exemption(s) an	d Exclusion(s) Claimed (se	lect all that apply)
	Investment Compa	ny Act Section 3(c)
Rule 504(b)(1) (not (i), (ii) or (ii	ii)) Section 3(c)(1)	Section 3(c)(9)
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(ii)		
Rule 504 (b)(1)(iii)	Section 3(c)(3)	Section 3(c)(11)
X Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)
	Section 3(c)(7)	

7. Type of Filing			
X New Notice Date of First Sale 2018-03-13 Find Amendment	rst Sale Yet to Occur		
8. Duration of Offering			
Does the Issuer intend this offering to last more th	an one year? Yes X No		
9. Type(s) of Securities Offered (select al	l that apply)		
X Equity	Pooled Investment Fund Interests		
Debt	Tenant-in-Common Securities		
Option, Warrant or Other Right to Acquire Anotl	her Mineral Property Securities		
Security to be Acquired Upon Exercise of Option Warrant or Other Right to Acquire Security	Other (describe)		
10. Business Combination Transaction			
Is this offering being made in connection with a but transaction, such as a merger, acquisition or exchange (if Necessary): 11. Minimum Investment			
11. William investment			
Minimum investment accepted from any outside i	nvestor \$10,000 USD		
12. Sales Compensation			
Recipient	Recipient CRD Number None		
National Securities Corporation	7569		
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X		
None	None		
Street Address 1	Street Address 2		
One Union Square	600 University Street, Suite 2900		
City	State/Province/Country ZIP/Postal Code		
eattle WASHINGTON 98101			
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US		
ARIZONA			
ARKANSAS			
CALIFORNIA			
COLORADO			

CONNECTICUT	
DISTRICT OF COLUMBIA	
FLORIDA	
GEORGIA	
ILLINOIS	
INDIANA	
MARYLAND	
MASSACHUSETTS	
MICHIGAN	
MINNESOTA	
NEVADA	
NEW JERSEY	
NEW YORK	
NORTH CAROLINA	
OKLAHOMA	
PENNSYLVANIA	
TEXAS	
UTAH	
VIRGINIA	
WASHINGTON	
WISCONSIN	
13. Offering and Sale Total Offering Amount	\$14,155,000 USD or Indefinite
Total Amount Sold	\$14,155,000 USD
Total Remaining to be So	ld \$0 USD or Indefinite
Clarification of Response (if Necessary):
14. Investors	
	ne offering have been or may be sold to persons who do not qualify as and enter the number of such non-accredited investors who already offering.
_	r securities in the offering have been or may be sold to persons who do ed investors, enter the total number of investors who already have g:
15. Sales Commission	s & Finder's Fees Expenses
	nounts of sales commissions and finders fees expenses, if any. If the amount of an , provide an estimate and check the box next to the amount.
Sales Com	missions \$1,415,500 USD Estimate
Find	ers' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

Represents 10% of the gross proceeds. The placement agent also received a warrant to purchase 10% of the number of shares of Series A Preferred Stock issued in the offering.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
TFF Pharmaceuticals, Inc.	/s/ Kirk Coleman	Kirk Coleman	Chief Financial Officer	2018-03-27

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their antifraud authority.